Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 195,838
  • Shares Outstanding, K 12,179
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,600 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 2.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Options Overview Details

View History
  • Implied Volatility 64.38% ( -9.68%)
  • Historical Volatility 50.16%
  • IV Percentile 4%
  • IV Rank 0.00%
  • IV High 222.54% on 09/19/24
  • IV Low 64.38% on 11/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 489
  • Volume Avg (30-Day) 950
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 13,390
  • Open Int (30-Day) 13,162

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.31
  • Number of Estimates 6
  • High Estimate -1.02
  • Low Estimate -1.52
  • Prior Year -1.81
  • Growth Rate Est. (year over year) +27.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.65 +7.86%
on 11/20/24
20.77 -18.73%
on 11/07/24
-0.79 (-4.47%)
since 10/21/24
3-Month
15.65 +7.86%
on 11/20/24
61.89 -72.73%
on 08/22/24
-44.67 (-72.58%)
since 08/21/24
52-Week
4.00 +322.00%
on 11/24/23
61.90 -72.73%
on 07/31/24
+12.68 (+301.90%)
since 11/21/23

Most Recent Stories

More News
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

CRBP : 16.89 (+5.04%)
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CRBP : 16.89 (+5.04%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 16.89 (+5.04%)
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

CRBP : 16.89 (+5.04%)
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRBP : 16.89 (+5.04%)
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

CRBP : 16.89 (+5.04%)
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

CRBP : 16.89 (+5.04%)
$SPX : 5,953.82 (+0.62%)
NVO : 103.07 (-2.09%)
MRK : 98.90 (+1.50%)
LLY : 750.05 (-0.45%)
ABBV : 172.09 (+2.58%)
PFE : 25.04 (+0.40%)
XBI : 94.77 (+0.81%)
BMY : 58.17 (+0.50%)
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

CRBP : 16.89 (+5.04%)
Corbus Pharmaceuticals: Q2 Earnings Snapshot

Corbus Pharmaceuticals: Q2 Earnings Snapshot

CRBP : 16.89 (+5.04%)
Up Over 700% YTD, Here's How Much Higher Analysts Think This Biotech Stock Can Rise

As the biotech industry rebounds from recent challenges, a favorable regulatory environment and groundbreaking scientific advancements are creating investment opportunities, particularly in companies with...

CRBP : 16.89 (+5.04%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 17.32
2nd Resistance Point 16.90
1st Resistance Point 16.49
Last Price 16.89
1st Support Level 15.66
2nd Support Level 15.24
3rd Support Level 14.83

See More

52-Week High 61.90
Fibonacci 61.8% 39.78
Fibonacci 50% 32.95
Fibonacci 38.2% 26.12
Last Price 16.89
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar